CHEMM ChemoMetec

Procedure of the Annual General Meeting

Procedure of the Annual General Meeting

ANNOUNCEMENT NO. 294



9 October 2025



Procedure of the Annual General Meeting

The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter.

At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2024/25 was approved, and the Board of Directors and the Executive Board were granted discharge.

The Annual General Meeting approved the proposal of the Board of Directors to distribute a dividend of DKK 7 per share of a nominal value of DKK 1.

The proposal presented by the Board of Directors that the Board of Directors continues to consist of 5 members was approved. Niels Thestrup, Martin Glensbjerg, Kristine Færch, Betina Hagerup and Peter Reich were re-elected to the Board of Directors.

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.

The Annual General Meeting approved the remuneration report, presented by the Board of Directors.

The proposal presented by the Board of Directors that the Board of Directors be granted authority to acquire treasury shares in the Company on behalf of the Company, was approved.

There were no other items for consideration, after which the general meeting was adjourned.

After the general meeting, a statutory board meeting was held, where Niels Thestrup was re-elected as chairman and Martin Glensbjerg as deputy chairman.



More information

Martin Helbo Behrens, CEO

Tel.: (+45) 48 13 10 20

Kim Nicolajsen, CFO

Tel.: (+45) 48 13 10 20



About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to



EN
09/10/2025

Underlying

CHEMMChemoMetec

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Vækst i omsætning og driftsresultat

Vækst i omsætning og driftsresultat Periodemeddelelse for 1. kvartal 2025/26 (1. juli - 30. september 2025) Vækst i omsætning og driftsresultat Omsætningen steg i 1. kvartal 2025/26 med 8% (11% ved faste valutakurser) til DKK 124,6 mio. fra DKK 115,6 mio. i samme periode sidste år. Udviklingen afspejler en fortsat fremgang i omsætningen af både instrumenter, forbrugsvarer og serviceydelser. ChemoMetec oplever endvidere en stigende interesse for vores teknologi, herunder ikke mindst XcytoMatic-platformen, og det forventes, at denne udvikling vil fortsætte og påvirke salg og indtjening posi...

3h / 20m 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Growth in revenue and operating profit

Growth in revenue and operating profit Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK 115.6 million in the year-earlier period. The Q1 performance reflected continued growth in sales of instruments, consumables and services. Moreover, ChemoMetec is experiencing growing interest in its technology, not least the XcytoMatic platform, and this trend is expected to continue, affecting sales and earnings positively, particularly in the latter pa...

3h / 20m 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Opjustering

Opjustering MEDDELELSE NR. 295 28. oktober 2025 Opjustering ChemoMetec oplever en stigende interesse for sin teknologi, herunder ikke mindst XcytoMatic platformen, og forventer som følge heraf en positiv udvikling i salg og indtjening i særligt den sidste del af regnskabsåret 2025/26. Der forventes således nu en omsætning i regnskabsåret 2025/26 på DKK 565-580 mio. mod senest udmeldt DKK 545-565 mio. mens EBITDA forventes at ligge i intervallet DKK 320-335 mio. mod senest udmeldt DKK 295-315 mio. ChemoMetecs periodemeddelelse for 1. kvartal 2025/26 forventes offentliggjort den 6. nov...

October 28, 2025 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Upgrade of guidance

Upgrade of guidance ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26. Consequently, revenue in the financial year 2025/26 is now expected to be DKK 565-580 million against the most recently announced DKK 545-565 million, while EBITDA is expected to be in the range of DKK 320-335 million compared to the most recently announced DKK 295-315 million. ChemoM...

October 28, 2025 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Forløb af ordinær generalforsamling

Forløb af ordinær generalforsamling MEDDELELSE NR. 294 9. oktober 2025 Forløb af ordinær generalforsamling Den ordinære generalforsamling i ChemoMetec A/S blev afholdt den 9. oktober 2025 kl. 17.30 hos Nordsjællands KonferenceCenter. På generalforsamlingen blev bestyrelsens beretning om selskabets virksomhed i det forløbne år fremlagt, årsrapporten for 2024/25 blev godkendt, og bestyrelsen samt direktionen blev meddelt decharge. Generalforsamlingen godkendte det af bestyrelsen fremsatte forslag om udlodning af udbytte på DKK 7 pr. aktie a nominelt DKK 1.  Bestyrelsens forslag om, ...

October 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch